{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:54:26Z","timestamp":1793318066514,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Tebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment-na\u00efve HLA-A*02:01\u2009+\u2009patients with unresectable or metastatic uveal melanoma (mUM). Notably, a survival benefit has been observed even in the absence of radiographic response. This study aims to investigate the feasibility and prognostic value of artificial intelligence (AI)-assisted quantification and metabolic response assessment of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG long axial field-of-view (LAFOV) PET\/CT in mUM patients undergoing tebentafusp therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Fifteen patients with mUM treated with tebentafusp underwent [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG LAFOV PET\/CT at baseline and 3\u00a0months post-treatment. Total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) were quantified using a deep learning-based segmentation tool On the RECOMIA platform. Metabolic response was assessed according to AI-assisted PERCIST 1.0 criteria. Associations between PET-derived parameters and overall survival (OS) were evaluated using Kaplan\u2013Meier survival analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median follow up (95% CI) was 14.1\u00a0months (12.9\u00a0months \u2013 not available). Automated TMTV and TLG measurements were successfully obtained in all patients. Elevated baseline TMTV and TLG were significantly associated with shorter OS (TMTV: 16.9 vs. 27.2\u00a0months; TLG: 16.9 vs. 27.2\u00a0months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Similarly, higher TMTV and TLG at 3\u00a0months post-treatment predicted poorer survival outcomes (TMTV: 14.3 vs. 24.5\u00a0months; TLG: 14.3 vs. 24.5\u00a0months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). AI-assisted PERCIST response evaluation identified six patients with disease control (complete metabolic response, partial metabolic response, stable metabolic disease) and nine with progressive metabolic disease. A trend toward improved OS was observed in patients with disease control (24.5 vs. 14.6\u00a0months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.08). Circulating tumor DNA (ctDNA) levels based on GNAQ and GNA11 mutations were available in 8 patients; after 3\u00a0months Of tebentafusp treatment, 5 showed reduced Or stable ctDNA levels, and 3 showed an increase (median OS: 24.5 vs. 3.3\u00a0months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.13). Patients with increasing ctDNA levels exhibited significantly higher TMTV and TLG on follow-up imaging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AI-assisted whole-body quantification of [1\u2078F]FDG PET\/CT and PERCIST-based response assessment are feasible and hold prognostic significance in tebentafusp-treated mUM. TMTV and TLG may serve as non-invasive imaging biomarkers for risk stratification and treatment monitoring in this malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07504-8","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:53:10Z","timestamp":1757148790000},"page":"1570-1580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET\/CT study"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-8741","authenticated-orcid":false,"given":"Christos","family":"Sachpekidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devayani","family":"Machiraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios Stefanos","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Kopp-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Edenbrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"7504_CR1","doi-asserted-by":"crossref","unstructured":"Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, Carvajal RD, Belfort RN, Jia R, Shields JA, Damato BE. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24. Erratum in: Nat Rev Dis Primers. 2022 Jan 17;8(1):4.","DOI":"10.1038\/s41572-020-0158-0"},{"issue":"1","key":"7504_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38\u201344.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"7504_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","volume":"29","author":"ES Rantala","year":"2019","unstructured":"Rantala ES, Hernberg M, Kivel\u00e4 TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561\u20138.","journal-title":"Melanoma Res"},{"issue":"8","key":"7504_CR4","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","volume":"30","author":"L Khoja","year":"2019","unstructured":"Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):1370\u201380.","journal-title":"Ann Oncol"},{"issue":"13","key":"7504_CR5","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206.","journal-title":"N Engl J Med"},{"issue":"10","key":"7504_CR6","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/14737140.2022.2124971","volume":"22","author":"LN Chen","year":"2022","unstructured":"Chen LN, Carvajal RD. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Expert Rev Anticancer Ther. 2022;22(10):1017\u201327.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"24","key":"7504_CR7","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, et al. Three-year overall survival with Tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256\u201366.","journal-title":"N Engl J Med"},{"issue":"5","key":"7504_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00262-014-1525-z","volume":"63","author":"G Bossi","year":"2014","unstructured":"Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ. Immtac-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother. 2014;63(5):437\u201348.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"7504_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102076","volume":"6","author":"JJ Sacco","year":"2025","unstructured":"Sacco JJ, Kirk P, Leach E, Shoushtari AN, Carvajal RD, Britton-Rivet C, et al. Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific. Cell Rep Med. 2025;6(4):102076.","journal-title":"Cell Rep Med"},{"issue":"2","key":"7504_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.cpet.2023.12.009","volume":"19","author":"ST Lee","year":"2024","unstructured":"Lee ST, Kovaleva N, Senko C, Kee D, Scott AM. Positron emission tomography\/computed tomography transformation of oncology: melanoma and skin malignancies. PET Clin. 2024;19(2):231\u201348.","journal-title":"PET Clin"},{"issue":"1","key":"7504_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40644-022-00512-z","volume":"22","author":"E Lopci","year":"2022","unstructured":"Lopci E, Aide N, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Perspectives on joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards for [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors. Cancer Imaging. 2022;22(1):73.","journal-title":"Cancer Imaging"},{"issue":"9","key":"7504_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091712","volume":"16","author":"SA Mirshahvalad","year":"2024","unstructured":"Mirshahvalad SA, Zamani-Siahkali N, Pirich C, Beheshti M. A systematic review and meta-analysis on the diagnostic and prognostic values of 18F-FDG PET in Uveal melanoma and its hepatic metastasis. Cancers (Basel). 2024;16(9):1712.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"7504_CR13","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1038\/s41598-025-88625-w","volume":"15","author":"TG Hindso","year":"2025","unstructured":"Hindso TG, Martinussen T, Bjerrum CW, Keller SH, Loft A, Sj\u00f8l MB, et al. 18F-FDG PET\/CT assessment of metabolic tumor burden predicts survival in patients with metastatic posterior uveal melanoma. Sci Rep. 2025;15(1):4110.","journal-title":"Sci Rep"},{"issue":"4","key":"7504_CR14","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s00259-022-06070-7","volume":"50","author":"C Sachpekidis","year":"2023","unstructured":"Sachpekidis C, Pan L, Kopp-Schneider A, Weru V, Hassel JC, Dimitrakopoulou-Strauss A. Application of the long axial field-of-view PET\/CT with low-dose [18F]FDG in melanoma. Eur J Nucl Med Mol Imaging. 2023;50(4):1158\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7504_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1274803","volume":"13","author":"T Wang","year":"2023","unstructured":"Wang T, Lei Y, Schreibmann E, Roper J, Liu T, Schuster DM, et al. Lesion segmentation on 18F-fluciclovine PET\/CT images using deep learning. Front Oncol. 2023;13:1274803. https:\/\/doi.org\/10.3389\/fonc.2023.1274803.","journal-title":"Front Oncol"},{"issue":"4","key":"7504_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2967\/jnumed.123.267048","volume":"65","author":"KH Leung","year":"2024","unstructured":"Leung KH, Rowe SP, Sadaghiani MS, Leal JP, Mena E, Choyke PL, et al. Deep semisupervised transfer learning for fully automated whole-body tumor quantification and prognosis of cancer on PET\/CT. J Nucl Med. 2024;65(4):643\u201350.","journal-title":"J Nucl Med"},{"key":"7504_CR17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269067","author":"CS Constantino","year":"2025","unstructured":"Constantino CS, Oliveira FPM, Machado M, Vinga S, Costa DC. The use of maximum-intensity projections and deep learning adds value to the fully automatic segmentation of lesions avid for [18F]FDG and [68Ga]Ga-PSMA in PET\/CT. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.124.269067.","journal-title":"J Nucl Med"},{"issue":"8","key":"7504_CR18","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00259-024-06668-z","volume":"51","author":"C Sachpekidis","year":"2024","unstructured":"Sachpekidis C, Enqvist O, Ul\u00e9n J, Kopp-Schneider A, Pan L, Mai EK, et al. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET\/CT predicts survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2024;51(8):2293\u2013307.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7504_CR19","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1109\/JBHI.2022.3230060","volume":"27","author":"TP Vagenas","year":"2023","unstructured":"Vagenas TP, Economopoulos TL, Sachpekidis C, Dimitrakopoulou-Strauss A, Pan L, Provata A, et al. A decision support system for the identification of metastases of metastatic melanoma using whole-body FDG PET\/CT images. IEEE J Biomed Health Inform. 2023;27(3):1397\u2013408.","journal-title":"IEEE J Biomed Health Inform"},{"key":"7504_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13046-025-03451-2","volume":"44","author":"D Machiraju","year":"2025","unstructured":"Machiraju D, Ziener CH, Clementi E, et al. Monitoring soluble cMET and ctDNA in metastatic uveal melanoma patients to track early disease progression on immunotherapies. J Exp Clin Cancer Res. 2025;44:213. https:\/\/doi.org\/10.1186\/s13046-025-03451-2.","journal-title":"J Exp Clin Cancer Res"},{"issue":"Suppl 1(Suppl 1","key":"7504_CR21","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1(Suppl 1)):122S-50S.","journal-title":"J Nucl Med"},{"issue":"1","key":"7504_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/cpf.12907","volume":"45","author":"T Skoglund","year":"2025","unstructured":"Skoglund T, Minarik D, Edenbrandt L, Tr\u00e4g\u00e5rdh E. High concordance of PET-CT treatment response evaluation according to PERCIST 1.0 when comparing images reconstructed with OSEM vs. BSREM. Clin Physiol Funct Imaging. 2025;45(1):e12907.","journal-title":"Clin Physiol Funct Imaging"},{"issue":"2","key":"7504_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576\u201384.","journal-title":"Radiology"},{"issue":"12","key":"7504_CR24","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s00259-023-06339-5","volume":"50","author":"C Sachpekidis","year":"2023","unstructured":"Sachpekidis C, Enqvist O, Ul\u00e9n J, Kopp-Schneider A, Pan L, Jauch A, et al. Application of an artificial intelligence-based tool in [18F]FDG PET\/CT for the assessment of bone marrow involvement in multiple myeloma. Eur J Nucl Med Mol Imaging. 2023;50(12):3697\u2013708.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7504_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2022.106902","volume":"221","author":"I Dirks","year":"2022","unstructured":"Dirks I, Keyaerts M, Neyns B, Vandemeulebroucke J. Computer-aided detection and segmentation of malignant melanoma lesions on whole-body 18F-FDG PET\/CT using an interpretable deep learning approach. Comput Methods Programs Biomed. 2022;221:106902.","journal-title":"Comput Methods Programs Biomed"},{"issue":"16","key":"7504_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164083","volume":"15","author":"I Dirks","year":"2023","unstructured":"Dirks I, Keyaerts M, Dirven I, Neyns B, Vandemeulebroucke J. Development and validation of a predictive model for metastatic melanoma patients treated with pembrolizumab based on automated analysis of whole-body [18F]FDG PET\/CT imaging and clinical features. Cancers (Basel). 2023;15(16):4083.","journal-title":"Cancers (Basel)"},{"key":"7504_CR27","doi-asserted-by":"publisher","unstructured":"Dell\u2019Oro\u00a0M,\u00a0Francis\u00a0RJ,\u00a0Gray\u00a0E, et al. Application of novel AI-assisted technology in\u00a018F-FDG PET-CT scan analysis \u2013 predicting disease response in metastatic melanoma patients undergoing immunotherapy. J ImmunoTher Cancer. 2023;11:https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0078.","DOI":"10.1136\/jitc-2023-SITC2023.0078"},{"key":"7504_CR28","doi-asserted-by":"publisher","unstructured":"Vagenas TP, Vakalopoulou M, Sachpekidis C, Dimitrakopoulou-Strauss A, Matsopoulos GK. Representation learning in PET scans enhanced by semantic and 3D position specific characteristics. IEEE Trans Med Imaging. 2025. https:\/\/doi.org\/10.1109\/TMI.2025.3566996. Epub ahead of print.","DOI":"10.1109\/TMI.2025.3566996"},{"issue":"Suppl 1","key":"7504_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00259-017-3687-3","volume":"44","author":"K Pinker","year":"2017","unstructured":"Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):55\u201366.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7504_CR30","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1007\/s00259-021-05282-7","volume":"48","author":"I Alberts","year":"2021","unstructured":"Alberts I, H\u00fcnermund JN, Prenosil G, Mingels C, Bohn KP, Viscione M, et al. Clinical performance of long axial field of view PET\/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48(8):2395\u2013404.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7504_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.semnuclmed.2024.05.008","volume":"55","author":"A Dimitrakopoulou-Strauss","year":"2025","unstructured":"Dimitrakopoulou-Strauss A, Pan L, Sachpekidis C. Total body PET-CT protocols in oncology. Semin Nucl Med. 2025;55(1):3\u201310.","journal-title":"Semin Nucl Med"},{"issue":"4","key":"7504_CR32","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00259-023-06534-4","volume":"51","author":"C Mingels","year":"2024","unstructured":"Mingels C, Caobelli F, Alavi A, Sachpekidis C, Wang M, Nalbant H, et al. Total-body PET\/CT or LAFOV PET\/CT? Axial field-of-view clinical classification. Eur J Nucl Med Mol Imaging. 2024;51(4):951\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7504_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT EANM procedure guidelines for tumour imaging version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7504_CR34","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2967\/jnumed.124.269203","volume":"66","author":"I Alberts","year":"2025","unstructured":"Alberts I, More S, Knapp K, Mei R, Fanti S, Mingels C, et al. Is long-axial-field-of-view PET\/CT cost-effective? An international health-economic analysis. J Nucl Med. 2025;66(6):954\u201360.","journal-title":"J Nucl Med"},{"issue":"2","key":"7504_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/CMR.0000000000000952","volume":"34","author":"NM Roshardt Prieto","year":"2024","unstructured":"Roshardt Prieto NM, Turko P, Zellweger C, Nguyen-Kim TDL, Staeger R, Bellini E, et al. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma. Melanoma Res. 2024;34(2):166\u201374.","journal-title":"Melanoma Res"},{"issue":"1","key":"7504_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10238-024-01497-8","volume":"24","author":"A Maurer","year":"2024","unstructured":"Maurer A, Clerici G, Schaab JA, Cheng PF, Mihic-Probst D, Mader C, et al. Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study. Clin Exp Med. 2024;24(1):234.","journal-title":"Clin Exp Med"},{"issue":"4","key":"7504_CR37","first-page":"225","volume":"38","author":"A Dimitrakopoulou-Strauss","year":"2023","unstructured":"Dimitrakopoulou-Strauss A, Sachpekidis C, Hassel JC, Christopoulos P. Positron emission tomography-based immunoimaging for cancer patient stratification: toward a more holistic approach. Cancer Biother Radiopharm. 2023;38(4):225\u201331.","journal-title":"Cancer Biother Radiopharm"},{"key":"7504_CR38","doi-asserted-by":"publisher","unstructured":"Wang C, Wang C, Zhang J, Ding M, Ge Y, He X. Development and validation of a radiogenomics prognostic model integrating PET\/CT radiomics and glucose metabolism-related gene signatures for non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07354-4. Epub ahead of print.","DOI":"10.1007\/s00259-025-07354-4"},{"issue":"supplement 2","key":"7504_CR39","first-page":"2454","volume":"63","author":"L Xie","year":"2022","unstructured":"Xie L, Hanyu M, Fujinaga M, Zhang L, Zhang Y, Hu K, et al. Theranostics of melanoma targeting metabotropic glutamate receptor 1 with a novel small-molecular radiopharmaceutical pair. J Nucl Med. 2022;63(supplement 2):2454.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07504-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:20Z","timestamp":1769834600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07504-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7504"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07504-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants enrolled in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish has been received from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Jessica C. Hassel discloses Speaker: Amgen, Bristol-Myers Squibb, GSK, Immunocore, Merck Sharp and Dohme, Novartis Pharma, Pierre Fabre, Sanofi-Aventis U.S. LLC; Sunpharma; Research grant\/contract: Bristol-Myers Squibb, Sanofi, Sunpharma; Consultant\/Advisory Board: Bristol-Myers Squibb, GSK, Immunocore, Merck Sharp and Dohme, Novartis Pharma, Pierre Fabre Pharmaceuticals Inc., Philogen, Onkowissen, Sanofi-Aventis U.S. LLC, Sun Pharmaceutical Industries Inc. All other authors declare no conflicts of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}